Media release
From: Springer Nature1. Health: Remission of systemic lupus erythematosus following CAR T therapy
Drug-free remission for up to 17 months has been demonstrated in five patients with systemic lupus erythematosus following CAR T cell therapy, reports a paper published in Nature Medicine.
Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease that occurs in approximately 0.1% of the global population, with a high prevalence in young women. This lifelong condition is driven by autoantibodies — immune defense molecules that attack the body’s own cells — and affects the joints and skin, potentially causing severe damage to organs, including the kidneys, brain and heart. Most patients are treated with glucocorticoids and therapies that target T cells or antibody-producing B cells. However, these treatments are frequently ineffective and no curative therapy is currently available.
Georg Schett and colleagues treated five patients (four women and one man; median age of 22 years) with treatment-resistant SLE with engineered anti-CD19 chimeric antigen receptor (CAR) T cells. These cells are designed to remove antibody-producing B cells by targeting the CD19 protein on their surface. At follow-up (3–17 months after treatment), all patients had experienced symptom improvement, including remission of internal organ involvement, as well as disappearance of disease-related autoantibodies, with no further need for conventional therapies. Common side effects associated with CAR T cell therapy were mild (for example, fever) and no infections were observed.
Although these findings may highlight a new therapeutic option for patients with SLE, longer follow-up in larger clinical trials is needed to determine the safety and efficacy of CAR T cell therapy in this context.
